Novo Nordisk

Lars Fruergaard Jørgensen, the CEO of Novo Nordisk, recently offered insights into several critical issues facing the pharmaceutical giant, including the ongoing

Novo Nordisk, the pharmaceutical powerhouse behind the blockbuster weight-loss and diabetes drug Ozempic, has faced a rare setback. The company’s pill-based version